Navigation Links
Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results
Date:3/25/2008

Company reports full year operating income of $856,000

IRVINE, Calif., March 25 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP), a leading developer of surgical products and accessories used in angina-relieving procedures, today reported financial results for its fourth quarter and fiscal year ended December 31, 2007.

Sales in the fourth quarter of 2007 totaled $2,767,000, a 24% decrease from the prior year fourth quarter sales of $3,664,000. During the fourth quarter of 2007, the Company sold three lasers and 462 handpiece units as compared to four lasers and 674 handpieces during the fourth quarter of 2006. The lower revenue in the current year quarter is primarily attributable to a $732,000, or 29%, decline in disposable handpiece revenue, and a $174,000, or 20%, decrease in capital sales as compared with the prior year quarter.

Sales for the year ended December 31, 2007 totaled $12,059,000, a decrease of approximately 30% from the $17,117,000 of sales recorded for the year ended December 31, 2006. The decrease in sales as compared with the prior year is primarily attributable to a $3,251,000, or 28%, decline in disposable handpiece revenue and a $1,927,000, or 43%, decline in capital sales. During the year ended December 31, 2007, the company sold 14 lasers and 2,293 handpieces as compared to 22 lasers and 3,162 handpieces in the prior year period.

"In addressing the reduction in sales during 2007, we are encouraged by the progress we have made in the second half of 2007 in expanding our sales force to support increasing sales going forward, finishing the year with 17 sales/clinical professionals in the field compared to 10 at the beginning of the year," commented Richard Lanigan, Cardiogenesis' President.

Cardiogenesis reported a fourth quarter 2007 operating loss of $32,000 as compared with an operating loss of $947,000 in the prior year quarter. The net loss for the quarter was $84,000,
'/>"/>

SOURCE Cardiogenesis Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cardiogenesis Corporation to Report Third Quarter 2007 Results on November 14th
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)..., NEW YORK, Dec. 1 Reportlinker.... available in its catalogue: ,, Industrial Enz...eportlinker.com/p0164431/Industrial-Enzymes---A-Gl...market is an oligopoly with few strong players and... activities. Keen competition and commoditization ...
(Date:12/1/2009)..., Former Majority Leader Richard Gephardt Brings ...e, Biotech Communities for "Best and Brightest Fo...J., Dec. 1 Several of N...ticals, research, medicine and technology gathered...e importance of medical innovation in New Jersey, ...
(Date:12/1/2009)...N FRANCISCO, Dec. 1 The Burrill Bi...f the value it lost in October. The Select,s gain ... month for the general markets with the Dow up 6.5...he gains held firm in the final two trading days o...h Thanksgiving holiday shopping and Dubai,s report...
(Date:12/1/2009)...ANBURY, N.J., Dec. 1 Pal...nnounced that the U.S. Patent and Trademark Office...lic Natriuretic Peptide Constructs." The claims i...unds that bind to natriuretic peptide receptor A (...lure drug candidate. ,, "Our natriuretic compou...
Breaking Biology Technology:Reportlinker Adds Industrial Enzymes - A Global Market Report 2Reportlinker Adds Industrial Enzymes - A Global Market Report 3Reportlinker Adds Industrial Enzymes - A Global Market Report 4Reportlinker Adds Industrial Enzymes - A Global Market Report 5Reportlinker Adds Industrial Enzymes - A Global Market Report 6Reportlinker Adds Industrial Enzymes - A Global Market Report 7Reportlinker Adds Industrial Enzymes - A Global Market Report 8Reportlinker Adds Industrial Enzymes - A Global Market Report 9Reportlinker Adds Industrial Enzymes - A Global Market Report 10New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 2New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 3New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 4New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 5Biotech Gets Back on Track in November 2Biotech Gets Back on Track in November 3Biotech Gets Back on Track in November 4Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 2Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 3
...g radio frequency identification (RFID) software f...en is the world,s largest manufacturer of cordless...Best Buy prompted Uniden to engage the supply chai...e telephone maker is using CatalystCommand iRFID t...y chain environment. , ,Uniden America Corp. is t...
...ll begins its 2005 season, researchers at the Uni... to demonstrate their school spirit. The only fans... high-powered microscopes. , ,Last month a team of...rs created "NanoBucky", an image of the universit...nometers long. With each nanofiber a thousandth th...
...tunity to define public discourse over nanotechnol...le information about the emerging technology, a Un... says. , ,"The message to scientists is: The publi...ur work to the public, and make it available where...ed one of the first national surveys on public kno...
Other Biology Technology:Nanotechnology minimizes UW's beloved mascot 2UW study examines public attitudes on nanotechnology 2
(Date:12/2/2009)... student at the University of Southampton,s School... Oceanography Centre, Southampton (NOCS) has forma...rom the deep sea. , Hall discovered the new spec... Museum of Natural History in Washington. Explaini...rabs include some of the largest crustaceans curre...
(Date:12/1/2009)...VALE, Calif., Dec. 1 GestureTek In... 3.0 - a turnkey, portable, plug and play interact...ibits, entertainment and touring promotions. Gestu...nts in camera-enabled gesture recognition technolo...tainment systems. ,, Guaranteed for quality, th...
(Date:12/1/2009)...inner of the 2009 Inserm Grand Prix., Every year... paying tribute to outstanding,work performed in ...ents, Inserm intends to,demonstrate the diversity...ogical, medical and,health research, and the crea...out and,drive this research each day. The Inserm ...
Breaking Biology News(10 mins):King crab family bigger than ever 2GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 2Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 2Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 3Abbott Expands XIENCE V 28R 29 USA Trial to Enroll Patients into Landmark Dual Anti Platelet Therapy 28DAPT 29 Trial 13549 1Abbott Expands XIENCE V 28R 29 USA Trial to Enroll Patients into Landmark Dual Anti Platelet Therapy 28DAPT 29 Trial 13549 2Abbott Expands XIENCE V 28R 29 USA Trial to Enroll Patients into Landmark Dual Anti Platelet Therapy 28DAPT 29 Trial 13549 3Abbott Expands XIENCE V 28R 29 USA Trial to Enroll Patients into Landmark Dual Anti Platelet Therapy 28DAPT 29 Trial 13549 4PharmAthene Reports Second Quarter 2009 Financial and Operational Results 13548 1PharmAthene Reports Second Quarter 2009 Financial and Operational Results 13548 2PharmAthene Reports Second Quarter 2009 Financial and Operational Results 13548 3PharmAthene Reports Second Quarter 2009 Financial and Operational Results 13548 4PharmAthene Reports Second Quarter 2009 Financial and Operational Results 13548 5PharmAthene Reports Second Quarter 2009 Financial and Operational Results 13548 6PharmAthene Reports Second Quarter 2009 Financial and Operational Results 13548 7PharmAthene Reports Second Quarter 2009 Financial and Operational Results 13548 8Boozing Blunts Ability to Read Faces 54415 1Boozing Blunts Ability to Read Faces 54415 2
...g on new methods to regenerate cartilage and bone ...to instruct them to turn into bone cells. The rese...ciences Research Council (BBSRC), could lead to a ...g populations of Western countries it holds the po...ng joint replacement or similar treatments. , The ...
... Biosciences AG today announced a collaboration to...o generate SNAP-tag fusion proteins based on Gene ...dge,s Red/ET cloning system does not require restr... DNA sequences, such as BACs, (bacterial artificia...NAP-tag is an intelligent self-labeling protein ta...
...ls are faced with everyday obstacles in their phys...sion-making and motor skills to deal with them. Na...x events in mammals and other vertebrates, but in ...bstacle-based system for studying the control and ...ruit fly Drosophila. , The findings are reported ...
Other Biology News:New research could help us deliver genes for new bone formation 2Gene Bridges And Covalys To Develop Restriction-Enzyme-Free SNAP-tag Gene Fusion Kits 2Gap-climbing fruit flies reveal components of goal-driven behaviors 2
...r 2-D separations. The cell has a six-gel capacity...II xi multi-cell can be customized for several par...nd cooling system. The PROTEAN II xi multi-cell ca...l for a wider format that accommodates 17 and 18 c...
PROTEAN II xi Cell, 16 cm, without spacers and combs from Bio-Rad
CleanCut Agarose, 2%, 12 ml from Bio-Rad
Safire 2 from Tecan
Biology Products: